Skip to main content
Sign In

Mark W. Geraci, M.D.

Professor of Medicine


  Mark W. Geraci, M.D.

  Head, Division of Pulmonary Sciences
    and Critical Care Medicine
  Professor of Medicine
  Director, Translational Medicine Program
  Co-Director, Colorado Clinical
    and Translational Sciences Institute’

  University of Colorado Denver
  Anschutz Medical Campus
  Division of Pulmonary Sciences and Critical Care Medicine
  MS C272, Research 2, Room 9019
  12700 E 19th Avenue
  Aurora, CO  80045
  303.724.6040 (office)
  303.724.6042 (fax)
  303.724.6037 (Assistant – Chris Weatherford)

Education/ Training
1979-1983   University of Colorado B.A.Molecular, Cellular, Boulder, Colorado Developmental Biology and Psychology    

1983-1987   Johns Hopkins University M.D. School of Medicine
                                    Baltimore, Maryland
Post Graduate
1987-1990   Massachusetts General Hospital  Internal Medicine Harvard Medical SchoolInternship and ResidencyBoston, Massachusetts

1990-1994   University of Colorado Fellowship Health Sciences Center Pulmonary Sciences and Critical Care Medicine Denver, Colorado

Honors and Service
1983    Phi Beta Kappa, Academic Honor Society, Graduate with Distinction, University of Colorado
1986    Lange Publications Medical Excellence Award, for highest academic performance Johns Hopkins SOM 
1987    Alpha Omega Alpha, Medical Honor Society, Johns Hopkins University School of Medicine
1994-1999       NHLBI K08 Clinical Investigator Development Award
2000-Pres       Ad Hoc Member, NIH Peer Review Study Sections (23 total), SBIR/STTR, NRSA, NINDS, NIEHS, NIAMS
2005-2009       Regular Member, NIH SMEP Study Section
2005-Pres       Editorial Board, Experimental Biology and Medicine
2006-Pres       Associate Editor, Clinical Translational Science
2009-Pres       Editorial Board, American Journal of Respiratory and Critical Care Medicine (AJRCCM)
2009-Pres       Editorial Board, American Journal of Respiratory Cell and Molecular Biology (AJRCMB)

Professional Experience
1987-1990       Medical Internship / Residency, Massachusetts General Hospital, Boston, MA
1990-1994       Fellow→Instructor, University of Colorado Denver, Denver, CO
1994-2005       Assistant Professor → Professor, Department of Medicine, UCDHSC, Denver, CO.
2005-Pres       Professor with Tenure, Department of Medicine, UCD, Denver, CO.
1999-Pres       Director, Genomics Core Facility, UCD, Denver, CO.
2004-Pres       Director, Translational Medicine Program, UCD, Denver, CO.
2004-Pres       Head, Division of Pulmonary Sciences and Critical Care Medicine, UCD, Denver, CO.

Research Interests

The Role of Eicosanoids in Pulmonary Hypertension and Lung Cancer: 
My laboratory has had a long-standing interest in the role of selected eicosanoids and their role in the development of both pulmonary hypertension and lung cancer.  We have accomplished the following:
• Cloning of the full-length rat prostacyclin synthase (PGIS) cDNA.
• Demonstration of decreased PGIS in primary pulmonary hypertension.
• Development of transgenic animals with pulmonary specific overexpression of PGIS
• Demonstration that these animals are completely protected form the development of pulmonary hypertension.
• Induction of pulmonary hypertension with targeted disruption of prostacyclin receptor.
• Prevention of tumorigenesis with PGIS overexpression.
• Lung cancer chemoprevention trial using Iloprost, a long-acting oral analogue of prostacyclin.  SPORE in Lung Cancer Administrative Supplement, National Institutes of Health, National Cancer Institute.  “A Randomized Phase II Chemoprevention Study of Iloprost versus Placebo in Patients at High Risk for Lung Cancer”. Grant # 3 P50 CA 58187-08S2. SPORE PI – Paul A. Bunn, Jr. MD. Supplement PI – Robert L. Keith MD. 11/01-12/08, $429,778 (Mentor on Project for Keith).